Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (Nasdaq: REPL) generates frequent news as a clinical stage biotechnology company developing novel oncolytic immunotherapies based on its proprietary HSV‑1‑derived RPx platform. Headquartered in Woburn, Massachusetts and founded in 2015, the company focuses on product candidates such as RP1 (vusolimogene oderparepvec) and RP2, which are being studied across multiple difficult‑to‑treat cancers.
News related to Replimune commonly covers clinical trial updates from programs like IGNYTE, IGNYTE‑3, ARTACUS and REVEAL. These updates include data presentations at major medical meetings, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, where the company has reported biomarker findings, response rates, durability of responses and safety data for RP1 plus nivolumab in advanced melanoma and non‑melanoma skin cancers.
Another major category of news involves regulatory milestones. Replimune has announced the FDA’s Complete Response Letter for the Biologics License Application (BLA) for RP1 in combination with nivolumab in advanced melanoma, subsequent Type A meetings with the FDA, and the agency’s acceptance of a BLA resubmission with a specified PDUFA target action date. These items are closely followed by investors and the oncology community because they reflect the evolving regulatory path for RP1.
Replimune’s news flow also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, and equity‑based inducement grants to employees, as well as participation in investor conferences like the J.P. Morgan Healthcare Conference. Together, these announcements provide insight into the company’s operational progress, clinical development priorities and interactions with regulators.
Investors, clinicians and other stakeholders can use this news feed to track key developments around Replimune’s RPx platform, its lead programs in advanced melanoma and skin cancers, and the broader pipeline in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.